CEO Fabrice Chouraqui spoke with Scrip about the company’s new $121m financing and its use of machine learning to target the whole cell instead of molecular targets in novel therapies.
Cellarity aims to move closer to the clinic with its whole-cell drug discovery and development approach, which is a departure from the industry’s dominant target-specific approach, with its latest round of venture capital financing.
The Somerville, Massachusetts-based company, built by Flagship Pioneering, said 4 October that it closed a $121m series C financing. Investors included Flagship along with others from its series B round, as well as new investors like Kyowa Kirin Co. Ltd
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process
Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.
